Report Overview

Indian Bone Disease market size stood at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.

The bone disease or Gorham-stout syndrome is a rare skeletal disease characterized by progressive osteolysis and the proliferation of lymphatic vessels within the bone which leads to the destruction and absorption of bone. Additionally, the bones affected by the disease are more prone to osteopenia and fracture. Vitamin D deficiency rickets in children and osteomalacia in the mothers are the commonest disorders prevalent in the rural population of India. Vitamin D deficiency osteomalacia and rickets caused by inadequate exposure to sunlight (290-315 nm), dietary calcium deficiency (<300 mg/day) and fluoride interaction syndromes, calcium deficiency induced osteoporosis and calcium and vitamin D deficiency induced osteoporosis in the elderly, were the commonest disorders responsible for bone disease and deformities, besides caused by endemic skeletal fluorosis as a single entity in endemic fluorosis villages. Calcium deficiency per se does not cause rickets, as revealed in our long-term follow up study on 47,500 calcium deficient children.The growing occurrence of the disease is the key driver for the growth of the market. Furthermore, current research for the development of the effective therapeutic intervention for the disease treatment is expected to contribute to the growth of the market.



Market Drivers

The growing occurrence of the Bone disease is the key driver for the growth of the market. Furthermore, current research for the development of the effective therapeutic intervention for the disease treatment is expected to contribute to the growth of the market. Rise in incidence rate of cancer, favorable reimbursement scenario, stringent regulatory policies assuring better product quality, increase in cancer research funding and new drug approvals, and surge in cancer awareness programs by governments and patient support organizations propel the bone disease market.